AusperBio
- Website
- ausperbio.com
- Total Funding
- $183.0M
- Last Round
- $120.0M Series CSep 2025
- Rounds
- 2
About
AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming HBV treatment for cure and advancing oligonucleotide therapeutics. Leveraging our innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, we strive to unleash the power of ASO therapeutics to treat a wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases, and to transform patient lives.
Summary
It has raised $183.0M in total across 2 rounds, most recently a $120.0M Series C round in Sep 2025. Investors include RA Capital Management, Hankang Capital and Qiming VP.
Tech & App Stack
1 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Sep 2025
Sign up to see all 2 rounds
Series C through Extension Round — per-round amounts, valuations, and who invested in each round.
Investors
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/ausperbio"><img src="https://indexed.vc/api/badge/company/ausperbio" alt="AusperBio on Indexed.vc" width="260" height="76" /></a>